P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. (23rd June 2022)

• Record Type: Journal Article
• Authors: Yu, W.; Wei, X.; Ge, Z.; Li, Y.; Jiang, Z.; Yang, L.; Lin, L.; Yao, Y.; Deng, X.; Du, X.; Li, Y.; Chen, T.; Feng, X.; Zhou, J.; Hou, M.; Fu, R.; Lan, J.; Hu, X.; Huang, S.; Wang, J.; Du, X.; Yang, H.; Yang, H.; Wang, H.; Zheng, L.; Wang, Z.; Liu, B.; Kang, N.; Zhuang, Y.; Zhang, Y.; Jin, J.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 490
• Page End: 491
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000845252.68424.50
• Languages: English
• ISSNs: 2572-9241